Related Experiment Video
Updated: Jan 16, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Joint association of plasma ceramide and renal function with coronary artery lesion severity: The CRUISE-MET study
Qiang Chen1, Yike Li1, Haoming He1
1Graduate School of Peking Union Medical College, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China (Drs Chen, Li, He, Xie, Yang, Zhou, and Zheng); Department of Cardiology, China-Japan Friendship Hospital, Beijing, China (Drs Chen, Li, He, Xie, D. Fu, Gao, Li, S. Fu, Mu, Sun, Yang, Zhou, Li, Gao, and Zheng).
Insights
Chronic kidney disease (CKD) and elevated ceramides, particularly Cer (18:1/16:0), synergistically increase the risk of complex coronary artery disease (CAD). This highlights the need for combined biomarker assessment and targeted therapies for atherosclerosis.
Area of Science:
- Cardiovascular Medicine
- Nephrology
- Biochemistry
Background:
- Ceramides and chronic kidney disease (CKD) are known independent risk factors for atherosclerosis.
- The synergistic impact of ceramides and CKD on coronary lesion severity is not well understood.
Purpose of the Study:
- To investigate the combined effect of specific ceramide species and renal dysfunction on coronary lesion complexity in patients with coronary artery disease (CAD).
Main Methods:
- Cross-sectional analysis of 691 CAD patients from the CRUISE-MET trial.
- Quantification of six ceramide species using ultra-high performance liquid chromatography-mass spectrometry/mass spectrometry.
- Classification of complex CAD (bSS > 22) and CKD (based on eGFR and UACR).
- Evaluation of combined and mediating effects of ceramides and renal dysfunction on coronary lesion complexity.
Main Results:
- Patients with complex lesions had elevated UACR, specific ceramides (Cer (18:1/16:0), Cer (18:1/18:0), Cer (18:1/24:1)), and decreased eGFR.
- Cer (18:1/16:0) showed the strongest correlation with baseline SYNTAX score (bSS) and highest predictive accuracy for complex CAD.
- Combined CKD and elevated Cer (18:1/16:0) significantly increased complex CAD risk (OR = 4.40).
- Renal impairment mediated a significant portion of ceramide's atherogenic effects.
Conclusions:
- Ceramide-renal synergy exacerbates coronary atherosclerosis.
- Integrated biomarker profiling of ceramides and renal function is recommended for risk stratification.
- Dual-targeted therapies addressing both ceramides and renal dysfunction may be beneficial for managing atherosclerosis.
Background:
Ceramides and chronic kidney disease (CKD) independently promote atherosclerosis, yet their synergistic effect remains underexplored. This study systematically investigates their combined impact on coronary lesion severity.
Method:
This cross-sectional analysis included coronary artery disease (CAD) patients from the CRUISE-MET trial (NCT06383208). Six ceramide species: Cer (18:1/16:0), Cer (18:1/18:0), Cer (18:1/20:0), Cer (18:1/22:0), Cer (18:1/24:0), and Cer (18:1/24:1), were quantified via ultra-high performance liquid chromatography-mass spectrometry/mass spectrometry. Baseline SYNTAX score (bSS) > 22 defined complex CAD. CKD was classified based on both estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio (UACR). The combined and mediating effects of ceramides and renal dysfunction on coronary lesion complexity were further evaluated.
Result:
Among 691 CAD patients, those with complex lesions exhibited elevated UACR, Cer (18:1/16:0), Cer (18:1/18:0), Cer (18:1/24:1), and decreased eGFR (all P < .05). Cer (18:1/16:0) demonstrated the strongest correlation with bSS (r = 0.186, P < .001) and highest predictive accuracy (area under the curve = 0.616). Multivariable-adjusted logistic regression revealed that per-SD increase in Cer (18:1/16:0) conferred 31% higher odds of complex CAD (odds ratio [OR] = 1.31, 95% CI: 1.08-1.59; P = .006), with the highest tertile showing 88% elevated risk (OR = 1.88, 95% CI: 1.18-3.01; P = .008). Synergistic effects were observed between CKD and elevated Cer (18:1/16:0) (> median), with combined exposure increasing complex CAD risk 4.4-fold (OR = 4.40, 95% CI: 2.74-7.07; P < .001). Mediation analysis implicated renal impairment in 28.1% (UACR) and 13.9% (eGFR) of ceramide's atherogenic effects. Sensitivity analyses confirmed robustness in diabetic and hypertensive subgroups.
Conclusion:
The study highlights ceramide-renal synergy in exacerbating coronary atherosclerosis, advocating integrated biomarker profiling for risk stratification and dual-targeted therapies.
More Related Videos
Related Concept Videos
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Coronary Artery Disease I: Introduction
Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease IV: Preventive Measures
Acute Coronary Syndrome III: Diagnostic Studies
Coronary Artery Disease III: Clinical Manifestations

